Phenotypic Analysis of Clinical Narratives Using Human Phenotype Ontology

Feichen Shen, Liwei Wang, Hongfang Liu
Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA

Abstract

Phenotypes are defined as observable characteristics and clinical traits of diseases and organisms. As connectors between medical experimental findings and clinical practices, phenotypes play vital roles in translational medicine. To facilitate the translation between genotype and phenotype, Human Phenotype Ontology (HPO) was developed as a semantically computable vocabulary to capture phenotypic abnormalities found in human diseases discovered through biomedical research. The use of HPO in annotating phenotypic information in clinical practice remains unexplored. In this study, we investigated the use of HPO to annotate phenotypic information in clinical domain by leveraging a corpus of 12.8 million clinical notes created from 2010 to 2015 for 729 thousand patients at Mayo Clinic Rochester campus and assessed the distribution information of HPO terms in the corpus. We also analyzed the distributional difference of HPO terms among demographic groups. We further demonstrated the potential application of the annotated corpus to support knowledge discovery in precision medicine through Wilson’s Disease.

Keywords
Semantic Annotation; Human Phenotype Ontology; Phenotypic Analysis

Introduction

Phenotypes, defined as observable characteristics and clinical traits of diseases and organisms, have attracted increasing attention in the area of translational medicine by serving as the connectors between medical experimental findings and clinical practices. For example, in genomic medicine, phenotypes provide evidence to stratify and differentiate various groups of patients in order to discover specific hidden genotype-phenotype associations [1].

As a tool for annotating human phenotypic abnormalities, Human Phenotype Ontology (HPO) [2] has been developed as a controlled vocabulary for phenotypes by mining and integrating phenotype knowledge from medical literatures, Orphanet [3], Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources...
(DECIPHER) [4], and Online Mendelian Inheritance in Man (OMIM) [5]. HPO also provides associations with other biomedical resources such as Gene Ontology [6]. Multiple studies have utilized HPO for data annotation. For example, Taboada [7] developed a semantic annotation system to automatically extract rare disease information from PubMed literature using HPO. In addition, Westbury and his colleagues [8] used a HPO-based clustering approach to identify group of heritable bleeding and platelet disorders (BPD) cases. Zhu and her colleagues [9] leveraged HPO to develop a genetic testing knowledge base.

Here, we used HPO to annotate a large collection of clinical narratives consisting of all clinical notes generated from 2010 to 2015 at Mayo Clinic Rochester campus and assessed the distributional information of HPO terms. A case study was performed to demonstrate the potential application of the annotated data.

In the following, we describe the methods used for generating the annotated corpus. Next, we present and discuss our results. We then analyze the distributional differences among demographic groups and detail the case study followed by the conclusion and potential future directions.

Background and Materials

Clinical Data Collection

We collected all clinical notes created between 2010 and 2015 at Mayo Clinic Rochester campus with research authorization. The resulting corpus contains 12.8 million clinical notes corresponding to 729 thousand patients. Specifically, we limited our annotation to the diagnosis section of clinical notes for better extracting phenotype related terms.

The Unified Medical Language System and MetaMap

The Unified Medical Language System (UMLS) [10] is an integrated database that contains all key medical terminologies and their related resources. Each term in the UMLS has a Concept Unique Identifier (CUI) and belongs to a specific semantic type. MetaMap [11] is a configurable application that is able to map biomedical terms to UMLS Metathesaurus. In this study, we applied MetaMap with the UMLS version 2015 on free-text clinical notes to extract related terms as a preprocessing step.

Human Phenotype Ontology

We used the latest version of Human Phenotype Ontology (HPO) released on September 2016. The HPO contains four sub-ontologies as shown in Table 1, and each sub-ontology has its different focus on annotating area.

HPO package contains an ontology file that records all HPO phenotype terms with their synonyms and resource references (e.g., the UMLS). As shown in Figure 1, in the ontology hierarchical structure, Menorrhagia (HP_0000132) belongs to sub-ontology Phenotypic Abnormality and is listed as a subclass of abnormal bleeding. Two synonyms abnormally heaving bleeding during menstruation and hypermenorrhea are connected to it through object property has_exact_synonym. Moreover, Menorrhagia relates to a UMLS CUI
C0025323 through Web Ontology Language (OWL) axiom and object property annotatedTarget. The corresponding Resource Description Framework (RDF) representation in Figure 1 indicates such triple relationships. Although HPO has link to the UMLS, the current version of HPO has not been fully incorporated into the UMLS version after 2013. Due to this limitation, the combination of both HPO and the UMLS is able to make a more comprehensive annotation than using only one of them.

In addition, there is another clinical annotation file wrapped in HPO package that captures around 119,000 phenotype-disease associations where a majority of them (115,000) correspond to hereditary conditions. Take Wilson’s Disease as an example, the HPO annotation file records 33 relevant phenotypes, e.g., Proteinuria, Dementia, and Coma etc.

Methods

Our annotation workflow is designed to leverage the UMLS and the corresponding NLP tool MetaMap. Figure 2 shows the overview of our annotation workflow, a combination of natural language processing (NLP) and semantic processing techniques. It includes two modules: i) the preprocessing module which leverages NLP techniques to extract key words from text; and ii) the semantic annotation module which maps the lexicon entries acquired from text to HPO terms and applies a greedy approach for each entry.

**NLP Preprocessing Module**

We first identify UMLS concepts in the diagnosis section of the clinical notes using MetaMap. We only keep UMLS concepts with the following phenotype-related semantic types: Disease or Syndrome (dsyn), Neoplastic Process (neop), Mental or Behavioral Dysfunction (mobd), Anatomical Abnormality (anab), Congenital Abnormality (cgab), Injury or Poisoning (inpo), Finding (findg) and Sign or Symptom (sosy).

**Semantic Annotation Module**

Our annotation focuses on the main HPO sub-ontology Phenotypic Abnormality (HP_0000118) and its descendants. It contains 11,721 phenotype terms and 19,358 related synonyms defined in HPO or inferred from the linked UMLS CUIs. Our mapping includes two steps: we map UMLS concepts derived from the NLP preprocessing module to HPO terms using exact match, in case of ambiguity, we select the one with the smallest CUI number; and for HPO terms that failed to be mapped to the UMLS, the module then conducts another round of string matching refinement. Specifically, it reviews tokenized original text to check if there exists any possible candidate missed by MetaMap.

**Results**

The proposed annotation system was developed with Eclipse Standard/SDK version Luna 4.4.0. The interface to access MetaMap, the UMLS, and HPO were coded in Java programming language. In addition, we deployed the whole system on the Open Grid Scheduler (OGS) framework running on 64 bit Linux CentOS 6.8 servers hosted by Mayo Clinic to improve processing speed on large amounts of clinical notes.
In the following, to protect patients’ privacy, any phenotypes with counts less than 11 were marked as <0.0015% or <11.

**HPO Phenotype Coverage in Clinical Data**

Overall, 3,241 out of 11,721 (27.7%) HPO phenotypes were extracted from 6,771,409 (52.8%) clinical notes. HPO has 23 abnormality categories. In our cohort, we counted the number of unique phenotypes and computed phenotype coverage for each category as shown in Figure 3. For example, *Abnormality of the nervous system* has the most phenotypes involved (599), e.g., *Anomia, Anxiety, Bone pain and Dysesthesia* while *Abnormality of the thoracic cavity* has no phenotype contained. Meanwhile, *Abnormality of the voice* holds a small group of phenotypes (11), including *Dysphonia, High pitched voice, Hoarse cry*, and *Laryngeal dystonia* etc. However, in terms of phenotype coverage, 78.6% (11 of 14) phenotypes under *Abnormality of the voice* were found. *Abnormality of the breast* also holds the second highest phenotype coverage as 55.6% (15 of 27). Since one phenotype can belong to more than one abnormality categories, in clinical notes, we found that 846 phenotypes are marked by 2 categories, 157 phenotypes dropped in 3 categories, 15 phenotypes are depicted by 4 categories, and only 1 phenotype is described by 5 categories.

Table 2 shows the top 10 frequent phenotypes as well as 10 phenotypes with relatively less frequent occurrences in clinical notes. We can see that many HPO common phenotype terms were found in cohort, such as *Hypertension, Hyperlipidemia, Apnea, or Anxiety*, etc.

We also noted our clinical notes contain phenotypes that related to rare diseases. For example, *Alacrima* is one of the features for *Triple A syndrome*. *Hemifacial hypertrophy* is a rare congenital disease. *Episodic tachypnea* often comes along with *Joubert syndrome*. *Alobar holoprosencephaly* is associated with *Holoprosencephaly*. *Barrel-shaped chest* is one of the symptoms of *Dyggve Melchior Clausen (DMC) syndrome*. *Chemodectoma* contributes to one of the signs caused by *Abdominal Chemodectomas with Cutaneous Angiolipomas*.

**Demographic Phenotype Analysis**

We retrieved patients’ associated demographic information and assessed the phenotype distributional difference among demographic groups.

We analyzed the distribution of HPO abnormality categories among different age groups. Basically, we grouped age 0-17, 18-35, 36-54 and >55 as children and teenagers, young adults, mid adults, and old adults age groups. As shown in Figure 4, *Abnormality of the nervous system* is popular in each age group. *Abnormality of immune system* occurs more frequently in children and teenagers. *Abnormality of the digestive system* often comes with young adult patients. While *Abnormality of the cardiovascular, skeletal, metabolism/homeostasis and respiratory systems* are common problems for mid adults but more common problems for old adults. In addition, *Immune system disorder, Abnormality of genitourinary system*, and *Neoplasm* have a high prevalence in old patients.

In total, there are 2,864 unique phenotypes found in male and 2,907 unique phenotypes detected in female. Based on patients’ percentile for both genders, we found that
Hypertension, Apnea, Hyperlipidemia, Back pain, and Obesity are 5 most frequently occurred common phenotypes. We also conducted two case-control studies on male and female respectively to discover dominant phenotypes for each gender. We ranked phenotypes by descending order of odds ratios and filtered out phenotypes that are only associated with one specific gender (e.g., Cryptorchidism for male and Amenorrhea for female). With the odds ratio of 13.6, Hypergonadotropic hypogonadism is the phenotype that closely related to male (Table 3). Meanwhile, Hirsutism shows the highest odds ratio of 94.3 with female (Table 4). In general, top phenotypes in female held a relative higher average odds ratio.

We also extracted 29 races from clinical notes and picked 2 with the most population (excluding other and unknown races), which are White (519,098) and Black or Africa (8,835). Based on phenotype frequencies, we found top 5 common phenotypes for both races are Hypertension, Apnea, Hyperlipidemia, Depression, and Back pain, which highly overlapped with top 5 common phenotypes for male and female except Depression. We also conducted two case-control studies on White and Black or Africa patients to acquire significant phenotypes for each race. Table 5 shows top 5 significant White-specific phenotypes based on odds ratio. Based on literature review, we validated that Basal cell carcinoma, Melanoma, and Macular degeneration are highly related to patients in white race [12–14]. Table 6 shows top 5 significant Black or Africa-specific phenotypes based on odds ratio with the number of affected patients greater than or equal to 3. We found that 4 out of 5 top Black or Africa-specific phenotypes are related to genetic and rare diseases. Scarring alopecia of scalp is a rare disorder that destroys hair follicle. Clitoral hypertrophy is a congenital malformation and a rare condition. Intellectual disability, profound is related to Lissencephaly. Spastic ataxia is a symptom of Autosomal Dominant Hereditary Ataxia. Except those rare phenotypes, Status asthmaticus is a severe asthma. Literature indicated that Scarring alopecia of scalp and Intellectual disability are related to Black or Africa patients [15–16]. For other 3 phenotypes, even they occur in few patients but it may be worth to explore more as little evidence has been found about the relationship between them and Black or Africa patients in literature.

A Case Study of Phenotypic Analysis

Wilson’s Disease (WD) is an autosomal recessive rare inherited disorder that makes copper accumulate in organs, and its diagnosis can be challenging as its signs and symptoms are often indistinguishable from those of other liver diseases, such as hepatitis. In this section, we conducted two case-control studies to demonstrate the potential of HPO-annotated data in supporting disease diagnosis. Among a total of 615,590 patients, we extracted 39 patients with confirmed diagnosis of WD and 63 patients suspected for WD but negative by genetic testing, leaving 615,488 patients with no clinical assertions or doubts for WD. Based on the three groups, two case-control studies were designed as follows: 1) To reveal significant phenotypes of WD, odds ratios of phenotypes were computed for 39 confirmed WD patients compared to 615,488 Non-WD patients; 2) To investigate the phenotypes significant for similar disease differentiation, odds ratios of phenotypes were computed for 39 confirmed WD patients compared to 63 patients suspected for WD.
Table 7 and 8 shows top 10 phenotypes ranked by odds ratio (with the number of affected patients greater than or equal to 3) representing significant clinical features of WD patients against the general population and the specific cohort with similar symptoms, respectively. Overall, odds ratio of phenotypes in the WD cohort against the general population were higher. Although the number of patients was relatively low, manual evaluation showed that all phenotypes are related to WD \cite{17–19}. In contrast, odds ratio of phenotypes in the WD cohort against the similar cohort were relative lower, reflecting the reality that differential difficulties exist in the diagnosis of WD and WD similar diseases. However, according to \cite{17}, 7 phenotypes Hypoalbuminemia, Nevus, Osteopenia, Cognitive impairment, Cirrhosis, Renal insufficiency, and Fever are common symptoms of WD, of which only Osteopenia and Cirrhosis are covered by WD-related phenotypes recorded in HPO annotation file. The remaining are possible comorbidities highly occurring with WD. This analysis revealed the potential of these phenotypes in differentiating WD from similar diseases.

**Discussion**

Our study showed that almost half of the clinical notes contain no HPO terms. To investigate further, we extracted top 10 frequent phenotypes from those notes including Fatigue, Pharyngitis, Dyslipidemia, Dermatoheliosis, Insomnia, Diabetes, Fibromyalgia, Snoring, Chronic Obstructive Airway Disease, and Rash. In general, most of these phenotypes are not hereditary ones, and some of them are more generic than HPO terms (e.g., SNOMED CT terms \cite{20}). For example, Fatigue covers HPO annotated phenotype Exercise-induced muscle fatigue, Pharyngitis gives a more general description of HPO annotated phenotype Recurrent Pharyngitis, and Diabetes is the super set of HPO annotated phenotype Insulin-resistant diabetes mellitus.

Note that in our case study, since Wilson’s Disease is a rare disease, we were not able to provide a large sample size, which results in relative low odds ratio and high p-value when compared confirmed patients to the general population and suspected patients. In addition, in this research, to reduce the confounding factor of comorbidity, we picked phenotypes at the same year with WD diagnosis. In the future, to further address this issue, a more specific timestamp can be added to put restriction on diagnosed period. Currently, HPO records 33 phenotypes specifically related to WD. Although HPO coverage for WD is not sufficient, phenotypes in HPO can help on extracting all symptoms of diseases, making it possible to reveal significant phenotypes of WD by conducting case-control analysis. Therefore, it is possible to combine clinical notes with HPO to provide empirical evidences to further help diagnose and differentiate WD from similar diseases.

The integration of genotypic and phenotypic knowledge is an essential step to facilitate knowledge discovery in translational medicine. HPO, as a tool with linkage to gene databases and statistics of patients’ percentile of phenotypes for each disease (e.g., 1% as very rare, 5% as rare), can be leveraged for this purpose. Especially for rare phenotypes, HPO makes it convenient for researchers to explore the potential genotype-phenotype associations.
Conclusions and Future Work

In this study, we used HPO to annotate phenotypes in clinical text for conducting phenotypic analysis. We demonstrated its potential in facilitating knowledge discovery.

In the future, we will try different ontologies and dictionaries to detect phenotypes from clinical notes and compare performances among them. Furthermore, a more specific diagnosis time range will be considered to largely reduce mischaracterization caused by complication and comorbidity. Moreover, we will use HPO with NLP and machine learning techniques to link various phenotypes with genes and drugs to perform knowledge discovery on gene disease and drug repositioning.

Acknowledgements

We would like to thank the support from our colleague Ravikumar Komandur Elayavilli for his valuable suggestions on this research. This work was made possible by internal funding from Center for Individualized Medicine of Mayo Clinic and NCATS Biomedical Translator Award, OT3TR00201901.

References

[1]. Denny Joshua C., et al. PheWAS: Demonstrating the feasibility of a phenome-wide scan to discover gene–disease associations. Bioinformatics 26 (2010), 1205–1210. [PubMed: 20335276]
[2]. Robinson Peter N., et al. The Human Phenotype Ontology: a tool for annotating and analyzing human hereditary disease. The American Journal of Human Genetics 83 (2008), 610–615. [PubMed: 18950739]
[3]. Weinreich Steffanie S., et al. Orphanet: a European database for rare diseases. Nederlands tijdschrift voor geneeskunde 152 (2008), 518–519. [PubMed: 18389888]
[4]. Firth Helen V., et al. DECIPHER: Database of chromosomal imbalance and phenotype in humans using ensembl resources. The American Journal of Human Genetics 84 (2009), 524–533. [PubMed: 19344873]
[5]. Hamosh Ada, et al. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic acids research 33suppl 1 (2005): D514–D517. [PubMed: 15608251]
[6]. Ashburner Michael, et al. Gene ontology: Tool for the unification of biology. Nature Genetics 25 (2000), 25–29. [PubMed: 10802651]
[7]. Taboada Maria, et al. Automated semantic annotation of rare disease cases: a case study. Database 2014 (2014): bau045. [PubMed: 24903515]
[8]. Westbury Sarah K., et al. Human phenotype ontology annotation and cluster analysis to unravel genetic defects in 707 cases with unexplained bleeding and platelet disorders. Genome Medicine 7 (2015), 1. [PubMed: 25606059]
[9]. Zhu Qian, et al. EHR based genetic testing knowledge Base (iGTKB) Development. BMC Medical Informatics and decision making 15 (2015), 1. [PubMed: 25889486]
[10]. Bodenreider Olivier. The unified medical language system (UMLS): Integrating biomedical terminology. Nucleic acids research 32suppl 1 (2004): D267–D270. [PubMed: 14681409]
[11]. Aronson Alan R. Effective mapping of biomedical text to the UMLS Metathesaurus: the MetaMap program. Proceedings of the AMIA Symposium. American Medical Informatics Association, 2001.
[12]. Chen Chih-Chiang, and Chen Chang-Lin. Clinical and histopathologic findings of superficial basal cell carcinoma: a comparison with other basal cell carcinoma subtypes. Journal of the Chinese Medical Association 69 (2006), 364–371. [PubMed: 16970272]
[13]. Linos Eleni, et al. Increasing burden of melanoma in the United States. Journal of Investigative Dermatology 129 (2009), 1666–1674. [PubMed: 19131946]
[14]. Frank Robert N., et al. Race, iris color, and age-related macular degeneration. Transactions of the American Ophthalmological Society 98 (2000), 109. [PubMed: 11190014]

[15]. Whiting David A., and Olsen Elise A.. Central centrifugal cicatricial alopecia. Dermatologic Therapy 21 (2008), 268–278. [PubMed: 18715297]

[16]. Maulik Pallab K., and Harbour Catherine K.. Epidemiology of intellectual disability. International Encyclopedia of Rehabilitation 2010

[17]. Available at: http://www.healthline.com/health/wilsonsdisease#Overview1

[18]. Schaefer Mark, et al. Increased prevalence of subcutaneous lipomas in patients with Wilson disease. Journal of clinical gastroenterology 49 (2015), e61–e63. [PubMed: 25291347]

[19]. Zhvania M, et al. Wilson disease with thrombocytopenia (case report). Georgian Medical News 237 (2014), 61–64.

[20]. Cote Roger A., et al. Progress in medical information management: Systematized nomenclature of medicine (SNOMED). JAMA 243 (1980), 756–762. [PubMed: 6986000]
Figure 1.
An Example of HPO Phenotype
Figure 2–.
Annotation Work Flow
Figure 3–.
Distribution and Coverage for HPO Categories
Figure 4–.
Distribution of Phenotypes across 4 Age Groups
### Table 1—

HPO Sub-ontologies

| Sub-ontology          | Description                                                                 |
|-----------------------|----------------------------------------------------------------------------|
| Phenotypic Abnormality | Main ontology of the HPO and covers most of the clinical abnormalities     |
| Mode of Inheritance   | Sub-ontology to describe mode of inheritance                               |
| Clinical Modifier     | Sub-ontology with description of typical modifiers of clinical symptoms    |
| Mortality/Aging       | Sub-ontology that indicates time of death                                   |
### Table 2–

**Selected HPO Annotated Common/Rare Phenotypes**

| Common Phenotypes | Patients’ Percentile | Rare Phenotypes | Patients’ Percentile |
|-------------------|----------------------|-----------------|---------------------|
| Hypertension      | 19.8%                | Alacrima        | <0.0015%            |
| Hyperlipidemia    | 15.2%                | Intercostal retractions | <0.0015%          |
| Depression        | 9.1%                 | Lattice retinal degeneration | <0.0015%          |
| Apnea             | 8.6%                 | Hemifacial hypertrophy | <0.0015%           |
| Back pain         | 8.5%                 | Decreased lacrimation | <0.0015%           |
| Obesity           | 8.4%                 | Episodic tachypnea | <0.0015%            |
| Sleep apnea       | 8.2%                 | Alobar holoprosencephaly | <0.0015%           |
| Anxiety           | 8.2%                 | Barrel-shaped chest | <0.0015%           |
| Headache          | 8%                   | Chemodectoma    | <0.0015%            |
| Arthritis         | 7.7%                 | Gastrointestinal carcinoma | <0.0015%          |
Table 3–

Top 5 Male-Specific Phenotypes

| Phenotype                            | #Patients | odds ratio | p-value   |
|--------------------------------------|-----------|------------|-----------|
| Hypergonadotropic hypogonadism       | 136       | 13.6       | 2.0e-31   |
| Violent behavior                     | 20        | 11         | 3.9e-05   |
| Dissecting aortic aneurysm           | 18        | 9.9        | 0.1e-03   |
| Calf muscle hypertrophy              | <11       | 9.9        | 0.9e-02   |
| Sinusitis                            | 9975      | 9.4        | 3.7e-158  |
## Table 4—

**Top 5 Female-Specific Phenotypes**

| Phenotype               | #Patients | odds ratio | p-value  |
|-------------------------|-----------|------------|----------|
| Hirsutism               | 1140      | 94.3       | 6.4e-298 |
| Hepatocellular adenoma  | 114       | 26         | 4.9e-27  |
| Bulimia                 | 417       | 23.7       | 3.4e-94  |
| Choroid plexus cyst     | 126       | 16.4       | 4.6e-27  |
| Neural tube defect      | 55        | 12.5       | 1.8e-11  |
### Table 5–

Top 5 White-Specific Phenotypes

| Phenotype              | #Patients | odds ratio | p-value |
|------------------------|-----------|------------|---------|
| Basal cell carcinoma   | 12969     | 113.2      | 3.2e-92 |
| Melanoma               | 20235     | 44.8       | 5.6e-136|
| Barrett esophagus       | 2899      | 16.5       | 1.9e-17 |
| Telangiectasia          | 1884      | 16.1       | 1.6e-11 |
| Macular degeneration    | 1330      | 11.3       | 8.5e-08 |
Table 6–

Top 5 Black or Africa-Specific Phenotypes

| Phenotype                          | #Patients | odds ratio | p-value |
|------------------------------------|-----------|------------|---------|
| Scarring alopecia of scalp         | <11       | 25.2       | 0.5e-03 |
| Clitoral hypertrophy               | <11       | 14.7       | 0.3e-03 |
| Intellectual disability, profound   | <11       | 13.6       | 0.2e-02 |
| Status asthmaticus                 | <11       | 11.8       | 0.1e-03 |
| Spastic ataxia                     | <11       | 11.8       | 0.3e-02 |
Table 7–
Top 10 Phenotypes with Odds Ratio for Confirmed WD Patients to Non-WD related Patients

| Phenotype                | #Patients | odds ratio | p-value  |
|--------------------------|-----------|------------|----------|
| Hepatic failure          | <11       | 22.5       | 0.4e-03  |
| Hypoalbuminemia          | <11       | 12.1       | 0.2e-02  |
| Cirrhosis                | 11        | 10.9       | 2.0e-08  |
| Elevated hepatic transaminases | <11 | 7.29       | 0.9e-02  |
| Splenomegaly             | <11       | 7.27       | 0.9e-02  |
| Ascites                  | <11       | 5.52       | 0.7e-02  |
| Encephalopathy           | <11       | 4.54       | 0.6e-02  |
| Hepatitis                | <11       | 4.02       | 0.5e-02  |
| Lipoma                   | <11       | 3.51       | 0.6e-01  |
| Thrombocytopenia         | <11       | 3.18       | 0.9e-02  |
Table 8—

Top 10 Phenotypes with Odds Ratio for Confirmed WD Patients to Suspected Patients

| Phenotype        | #Patients | odds ratio | p-value |
|------------------|-----------|------------|---------|
| Hyperglycemia    | <11       | 5.2        | 0.2     |
| Hypoalbuminemia  | <11       | 5.2        | 0.2     |
| Nevus            | <11       | 3.5        | 0.2     |
| Esophagitis      | <11       | 2.5        | 0.4     |
| Osteopenia       | <11       | 2.5        | 0.4     |
| Cognitive impairment | <11  | 2.5        | 0.4     |
| Hyperlipidemia   | <11       | 2.54       | 0.2     |
| Cirrhosis        | 11        | 2.08       | 0.2     |
| Renal insufficiency | <11 | 2.06       | 0.3     |
| Fever            | <11       | 1.71       | 0.5     |